Molecular subtypes of breast carcinoma in Egyptian women: Clinicopathological features

Pathology Research and Practice

Volumn 208, Issue 7, 2012, Pages 382-386

  El Hawary, Amira K ^a   Abbas, Ahmed S ^a   Elsayed, Ahmed A ^a   Zalata, Khaled R ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Breast carcinoma; Egyptian women; Molecular subtypes

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER SIZE; CANCER SURGERY; EGYPTIAN; ETHNIC GROUP; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDULLARY CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARCINOMA, MEDULLARY; EGYPT; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; NEOPLASM GRADING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84863819204     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2012.03.011     Document Type: Article

References (37)

1. Abd El-Rehim D.M., Ball G., Pinder S.E., Rakha E., Paish C., Robertson J.F., Macmillan D., Blamey R.W., Ellis I.O. High-throughput protein expression analysis using tissue microarray technology of a large well characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int. J. Cancer 2005, 116:340-350.
2. Allred D.C., Harvey J.M., Berardo M., Clark G.M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 1998, 11:155-168.
3. Bauer K.R., Brown M., Cress R.D., Parise C.A., Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple negative phenotype: a population-based study from the California cancer Registry. Cancer 2007, 109:1721-1728.
4. Ben Abdelkrim S., Trabelsi A., Missaoui N., Beizig N., Bdioui A., Anjorin A., Jomaa W., Mokni M. Distribution of molecular breast cancer subtypes among Tunisian women and correlation with histopathological parameters: a study of 194 patients. Pathol. Res. Pract. 2010, 206:772-775.
5. Bertucci F., Finetti P., Cervera N., Charafe-Jauffret E., Mamessier E., Adelaide J., Debono S., Houvenaeghel G., Maraninchi D., Viens P., et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 2006, 66(9):4636-4644.
6. Blows F.M., Driver K.E., Schmidt M.K., Broeks A., van Leeuwen F.E., Wesseling J., Cheang M.C., Gelmon K., Nielsen T.O., Blomqvist C., Heikkila P., Heikkinen T., Nevanlinna H., Akslen L.A., Begin L.R., Foulkes W.D., Couch F.J., Wang X., Cafourek V., Olson J.E., Baglietto L., Giles G.C., Severi G., McLean C.A., Southey M.C., Rakha E., Green A.R., Ellis I.O., Sherman M.E., Lissowska J., Anderson W.F., Cox A., Cross S.S., Reed M.W.R., Provenzano E., Dawson S.J., Dunning A.M., Humphreys M., Easton D.F., García-Closas M., Caldas C., Pharoah P.D., Huntsman D. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010, 7:e1000279.
7. Del Casar J.M., Martín A., García C., Corte M.D., Alvarez A., Junquera S., et al. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2008, 141:147-152.
8. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., Lickley L.A., Rawlinson E., Sun P., Narod S.A. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 2007, 13:4429-4434.
9. Dent R., Trudeau M., Pritchard K., Hanna W.M., Kahn H.K., Sawka C.A., Lickley L.A., Rawlinson E., Sun P., Narod S.A. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 2007, 13(15):4429.
10. Dunnwald L.K., Rossing M.A., Li C.I. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007, 9:R6.
11. Ellis I.O., Schnitt S.J., Sastre-Garau X., Bussolati G., Tavassoli F.A., Eusebi V., Peterse J.L., Mukai K., Tabar L., Jacquemier J., Cornelisse C.J., Sasco A.J., Kaaks R., Isani P., Goldgar D.E., Devilee P., Cleton-Jansen M.J., Borresen-Dale A.L., van't Veer L., Sapino A. Invasive breast carcinoma. World Health Organization classification of tumors. Pathology and genetics of tumors of the breast and female genital organs 2003, 13-59. IARC Press, Lyon. F.A. Tavassoli, P. Devilee (Eds.).
12. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
13. Hugh J., Hanson J., Cheang M.C., Nielsen T.O., Perou C.M., Dumontet C., Reed J., Krajewska M., Treilleux I., Rupin M., Magherini E., Mackey J., Martin M., Vogel C. Breast cancer subtypes and response to docetaxel in node positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J. Clin. Oncol. 2009, 27:1168-1176.
14. Huo D., Ikpatt F., Khramtsov A., Dangou J.M., Nanda R., Dignam J., et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J. Clin. Oncol. 2009, 27:4515-4521.
15. Ibrahim E., Al-Gahmi A.M., Zeenelin A.A., Zekri J.M., Elkhodary T.R., Gaballa H.E., Fawzy E.E., El sayed M.E., Alzahrani M.S. Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers. Med. Oncol. 2009, 26:372-378.
16. Jung S.Y., Jeong J., Shin S.H., Kwon Y., Kim E.A., Ko K.L., Shin K.H., Lee K.S., Park I.H., Lee S., Kim S.W., Kang H.S., Ro J. The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study. BMC Cancer 2010, 10:664.
17. Kim M.J., Ro J.Y., Ahn S.H., Kim H.H., Kim S.B., Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum. Pathol. 2006, 37:1217-1226.
18. Kim S.I., Sohn J., Koo J.S., Park S.H., Park H.S., Park B.W. Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Oncology 2010, 79:324-330.
19. Laakso M., Tanner M., Nilsson J., Wiklund T., Erikstein B., Kellokumpu-Lehtinen P., Malmström P., Wilking N., Bergh J., Isola J. Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin. Cancer Res. 2006, 12:4185-4191.
20. Livasy C.A., Karaca G., Nanda R., Tretiakova M.S., Olopade O.I., Moore D.T., Perou C.M. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod. Pathol. 2006, 19:264-271.
21. Marginean F., Rakha E.A., Ho B.C., Ellis I.O., Lee A.H.S. Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast. Mod. Pathol. 2010, 23:1357-1363.
22. Millikan R.C., Newman B., Tse C.K., Moorman P.G., Conway K., Dressler L.G., Smith L.V., Labbok M.H., Geradts J., Bensen J.T., Jackson S., Nyante S., Livasy C., Carey L., Earp H.S., Perou C.M. Epidemiology of basal like breast cancer. Breast Cancer Res. Treat. 2008, 109:123-139.
23. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lønning P.E., Børresen-Dale A.L., Brown P.O., Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
24. Omar S., Khaled H., Gaafar R., Zekry A.R., Eissa S., El-Khatib O. Breast cancer in Egypt: a review of disease presentation and detection strategies. East Mediterr. Health J. 2003, 9:448-463.
25. Rakha E.A., El-Sayed M.E., Green A.R., Lee A.H., Robertson J.F., Ellis I.O. Prognostic markers in triple-negative breast cancer. Cancer 2007, 109:25-32.
26. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., Rijn V.D., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Lønning P.E., Børresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:10869-10874.
27. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., Demeter J., Perou C.M., Lønning P.E., Brown P.O., Børresen-Dale A.L., Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:8418-8423.
28. Sorlie T., Wang Y., Xiao C., Johnsen H., Naume B., Samaha R.R., Børresen-Dale A.L. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 2006, 7:127.
29. Spitale A., Mazzola P., Soldini D., Mazzucchelli L., Bordoni A. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population based study from the South of Switzerland. Ann. Oncol. 2009, 20:628-635.
30. Stark A., Kleer C., Martin I., Awuah B., Nsiah-Asare A., Takyi V., Braman M., Quayson S.E., Zarbo R., Wicha M., Newman L. African ancestry and higher prevalence of triple-negative breast cancer. Findings from an international study. Cancer 2010, 116:4926-4932.
31. Thike A.A., Cheok P.Y., Jara-Lazaro A.R., Tan B., Tan P., Tan P.H. Triple negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod. Pathol. 2010, 23:123-133.
32. Tian X.S., Cong M.H., Zhou W.H., Zhu J., Chen Y.Z., Liu Q. Clinicopathologic and prognostic characteristics of triple-negative breast cancer. Onkologie 2008, 31:610-614.
33. Weigelt B., Horlings H.M., Kreike B., Hayes M.M., Hauptmann M., Wessels L.F., de Jong D., Van de Vijver M.J., Van't Veer J.L., Peterse J.L. Refinement of breast cancer classification by molecular characterization of histological special types. J. Pathol. 2008, 216:141-150.
34. Wiechmann L., Sampson M., Stempel M., Jacks L.M., Patil S.M., King T., et al. Presenting features of breast cancer differ by molecular subtype. Ann. Surg. Oncol. 2009, 16:2705-2710.
35. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., Dowsett M., Fitzgibbons P.L., Hanna W.M., Langer A., McShane L.M., Paik S., Pegram M.D., Perez E.A., Press M.F., Rhodes A., Sturgeon C., Taube S.E., Tubbs R., Vance G.H., van de Vijver M., Wheeler T.M., Hayes D.E. American Society of Clinical Oncology; College of American Pathologists American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007, 25:118-145.
36. Yang X.R., Sherman M.E., Rimm D.L., Lissowska J., Brinton L.A., Peplonska B., Hewitt S.M., Anderson W.F., Szeszenia-Dabrowska N., Bardin Mikolajczak A., Zatonski W., Cartun R., Mandich D., Rymkiewicz G., Ligaj M., Lukaszek S., Kordek R., García-Closas M. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol. Biomarkers Prev. 2007, 16:439-443.
37. Zaha D.C., Lazǎr E., Lǎzureanu C. Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer. Rom. J. Morphol. Embryol. 2010, 51:85-89.